Literature DB >> 22478777

Specialty pharmacy trends and plan sponsor value.

F Randy Vogenberg.   

Abstract

Current benefit designs can't handle the increasing use and cost of biologic therapies. New tactical strategies to forge value-based insurance are needed now.

Year:  2009        PMID： 22478777      PMCID： PMC2799084     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN： 1554-169X


  1 in total

Review 1.  Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.

Authors:  Quan V Doan; Chiun-Fang Chiou; Robert W Dubois
Journal:  J Manag Care Pharm       Date:  2006-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.